195 related articles for article (PubMed ID: 38062630)
1. Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
Brissenden JA; Scerbak T; Albin RL; Lee TG
Mov Disord; 2024 Jan; 39(1):76-84. PubMed ID: 38062630
[TBL] [Abstract][Full Text] [Related]
2. Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease.
Zappia M; Colao R; Montesanti R; Rizzo M; Aguglia U; Gambardella A; Oliveri RL; Quattrone A
Ann Neurol; 1997 Aug; 42(2):245-8. PubMed ID: 9266736
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-duration responses to levodopa during the first year of levodopa therapy.
Nutt JG; Carter JH; Van Houten L; Woodward WR
Ann Neurol; 1997 Sep; 42(3):349-55. PubMed ID: 9307256
[TBL] [Abstract][Full Text] [Related]
4. Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
Sciacca G; Mostile G; Disilvestro I; Donzuso G; Nicoletti A; Zappia M
Mov Disord; 2023 Apr; 38(4):626-635. PubMed ID: 36840442
[TBL] [Abstract][Full Text] [Related]
5. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
6. Integrated robotics platform with haptic control differentiates subjects with Parkinson's disease from controls and quantifies the motor effects of levodopa.
Gaprielian P; Scott SH; Lowrey C; Reid S; Pari G; Levy R
J Neuroeng Rehabil; 2019 Oct; 16(1):124. PubMed ID: 31655612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Parkinson's KinetiGraph to off/on levodopa response testing: Single center experience.
Guan I; Trabilsy M; Barkan S; Malhotra A; Hou Y; Wang F; Hellmers N; Sarva H; Henchcliffe C
Clin Neurol Neurosurg; 2021 Oct; 209():106890. PubMed ID: 34455169
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
[TBL] [Abstract][Full Text] [Related]
9. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
11. Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
Donzuso G; Sciacca G; Rascunà C; Cicero CE; Mostile G; Nicoletti A; Zappia M
J Neurol; 2021 Nov; 268(11):4258-4264. PubMed ID: 33864515
[TBL] [Abstract][Full Text] [Related]
12. Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication.
Kojovic M; Mir P; Trender-Gerhard I; Schneider SA; Pareés I; Edwards MJ; Bhatia KP; Jahanshahi M
J Neurol; 2014 Jun; 261(6):1080-9. PubMed ID: 24687892
[TBL] [Abstract][Full Text] [Related]
13. MAO and L-dopa treatment of Parkinson's disease.
Tyce GM; Dousa MK; Muenter MD
J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
[TBL] [Abstract][Full Text] [Related]
14. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa.
Rampello L; Chiechio S; Raffaele R; Vecchio I; Nicoletti F
Clin Neuropharmacol; 2002; 25(1):21-4. PubMed ID: 11852292
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Papapetropoulos S; Liu W; Duvvuri S; Thayer K; Gray DL
Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
[TBL] [Abstract][Full Text] [Related]
16. Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.
Wider C; Russmann H; Villemure JG; Robert B; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
Arch Neurol; 2006 Jul; 63(7):951-5. PubMed ID: 16831963
[TBL] [Abstract][Full Text] [Related]
17. Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
ZhuParris A; Thijssen E; Elzinga WO; Makai-Bölöni S; Kraaij W; Groeneveld GJ; Doll RJ
Mov Disord; 2023 Oct; 38(10):1795-1805. PubMed ID: 37401265
[TBL] [Abstract][Full Text] [Related]
18. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
[TBL] [Abstract][Full Text] [Related]
19. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
[TBL] [Abstract][Full Text] [Related]
20. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
